News Headlines
-
FUJIFILM Diosynth Invests $1.2B In Holly Springs, North Carolina, Manufacturing Facility, Creating 680 New Jobs
4/11/2024
FUJIFILM Diosynth Biotechnologies North Carolina, Inc., a world-leading contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County.
-
Baxter Expands Pharmaceuticals Portfolio With New Injectable Products In The U.S.
4/11/2024
Baxter International Inc. a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S.
-
NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement To Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials
4/10/2024
NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the signing of a Clinical Supply Agreement with Clarity Pharmaceuticals for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials.
-
Asahi Kasei Bioprocess And Axolabs Announce Strategic Partnership To Accelerate Oligonucleotide Therapeutics Development
4/10/2024
Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have announced a strategic partnership in the burgeoning field of oligonucleotide therapeutics.
-
Sen-Jam Pharmaceutical Partners With Specialty Pharmaceutical Manufacturer To Provide Formulation And Chemistry, Manufacturing & Controls For Revolutionary Anti-Inflammatory Injectable
4/10/2024
Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel uses, has entered a third strategic partnership with KVK-Tech. KVK-Tech is a leading Specialty Pharmaceutical Manufacturing company that will be providing formulation and Chemistry, Manufacturing & Controls (CMC) for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100.
-
ChromaTan And Batavia Receive NIIMBL Grant To Integrate Column-Free Steady-State Continuous Elution Chromatography Into HIP-Vax Manufacturing Platform For AAV
4/10/2024
ChromaTan, a bioprocessing and biotools advanced biomanufacturing technology platform development company, is excited to announce an alliance with Batavia Biosciences, a leading contract development and manufacturing organization, for the development and integration of ChromaTan’s BioRMBTM continuous counter-current elution technology into Batavia’s AAV HIP-Vax manufacturing platform.
-
Ascend Acquires GMP Manufacturing Capacity In Alachua, Florida; Enters Long-Term Partnership With Beacon Therapeutics For Clinical And Commercial AAV Production
4/9/2024
Ascend Advanced Therapies (Ascend), a total solutions gene therapy development partner, has acquired the CMC team and site in Alachua, Florida from Beacon Therapeutics (Beacon). The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team. It also includes a long-term partnership with Beacon to continue manufacturing its products for clinical and commercial use, securing product supply for Beacon and enabling it to focus on clinical development.
-
Virtuosi Becomes An IACET Accredited Provider
4/9/2024
The International Accreditors for Continuing Education and Training (IACET) has awarded Virtuosi the prestigious Accredited Provider accreditation.
-
Kindeva Drug Delivery And Syntegon Install First Versynta Microbatch In North America
4/9/2024
Syntegon today announced the sale of its newly developed Versynta microBatch production cell to its first U.S. customer. Kindeva Drug Delivery will use Versynta microBatch to further expand its suite of aseptic fill-finish contract development and manufacturing (CDMO) capabilities meeting the latest global pharmaceutical regulations and trends.
-
Charles River Announces Rare Disease Gene Therapy Collaboration With Axovia Therapeutics
4/9/2024
Charles River Laboratories International, Inc. today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.